Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to adescription of mandibular osteomylitis in patients having had a treatment by DENOSUMAB. Indeed, one of the adverse effect ot this molecule is to induce mandibular infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mandibular osteomylitis | description of mandibular osteomylitis due to denosumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| mandibular osteomylitis | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of mandibular osteomyelitis | description of mandibular osteomyelitis | Entire description can be made at the outcome which is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of antibiotics | Description of the duration and strategies of antibiotic treatments used (double-agent therapy, monotherapy) | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Rate of Treatment Failure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
patients having a mandibular osteomylelitis due to DENOSUMAB betwwen 01/01/2013 and 31/12/2018 and managed at the Lyon Bone and joint infection refence Center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| TRISTAN FERRY, MD,PhD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010019 | Osteomyelitis |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D001850 | Bone Diseases, Infectious |
| D007239 | Infections |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. |
| Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| management of mandibular osteomyelitis by medical team | description of medical and surgical strategies : data availables in consultation report | all data are available at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| D064419 |
| Chemically-Induced Disorders |